Enbrel Maxing Out: Wyeth Sees Sales At Top End Of Forecast
This article was originally published in The Pink Sheet Daily
Executive Summary
Wyeth is "more confident than ever" that Enbrel will be "category leader" for TNF inhibitors, firm says. Enbrel on track for about $1.8 bil. in revenues this year.